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Transfusion medicine has undergone dramatic changes
through the centuries. In the early 1900s Karl Landsteiner
discovered the ABO blood group system, which allowed
blood products to be administered without precipitating
immediate severe transfusion reactions. The logistics for col-
lecting and storing blood followed at the time of the onset of
World War I, with the introduction of the anticoagulant
trisodium citrate to prevent clotting. The mid-20th century
was focused on attempts to have adequate blood supply on
hand, as operative procedures became technically more
complex and medical specialties known to consume large
quantities of blood and blood products, such as transplanta-
tion, began to emerge. Contamination of the blood supply
also was becoming a concern, and in the early 1970s it was
recognized that the incidence of hepatitis transmission could
be decreased by excluding paid donors. Screening for
hepatitis B became standard shortly thereafter. Until 1980,
blood donations were only screened for syphilis serology and
hepatitis B. Since then, nine new blood tests have been intro-
duced in an attempt to reduce the transmission of HIV-1, HIV-2,
hepatitis C, and human T-cell leukemia virus (HTLV)-I and
HTLV-II [1]. By 1996, anti-HIV-1 and p24 antigen testing
were routinely performed, decreasing the transmission of HIV.
Despite these advances, there continues to be major con-
cerns with our blood supply because of bovine spongiform
encephalopathy, prion transmission, and unknown
pathogens. As we continue into the new millennium, interests
are shifting toward technologic advances in pathogen inacti-
vation and modification of the red blood cell (RBC) surface to
reduce antigenicity [1].
Leukoreduction is a process in which the white cells, ordinar-
ily present in collected blood components, are intentionally
reduced in number. Through the use of centrifugation or filtra-
tion, 99.995% leukocyte reduction can be accomplished.
Cytomegalovirus (CMV), HTLV-I, and HTLV-II are only trans-
mitted by transfusion of cellular products, and if universal
leukoreduction were to be adopted then these viruses would
be removed by filtration, and it would no longer be necessary
to test for these potential contaminants. Thus, an advantage
of leukoreduction is its effectiveness in reducing the transmis-
sion of cell-associated viruses, especially CMV, her-
pesviruses, and Epstein–Barr virus. Leukoreduction filters
also bind the Trypanosoma cruzi parasite and may decrease
the incidence of transfusion-associated Chagas’ disease [2].
In 1998, the Blood Products Advisory Committee of the US
Food and Drug Administration unanimously voted in favor of
universal leukoreduction of blood components, but its
members agreed that sufficient evidence-based data were
lacking. Thus, both leukoreduced and nonleukoreduced
blood components currently remain approved by the Food
and Drug Administration. In 1994 and 1997, the percentage
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Abstract
The safety of the blood supply has been a concern over the past 20–30 years because of the
transmission of infectious diseases. Blood is still routinely tested for viruses, and leukoreduction is an
effective strategy to reduce the transmission of cell-associated viruses. Clinically, the benefits of
leukoreduction include decreases in transfusion reactions, HLA alloimmunization, infections, fever
episodes, and antibiotic use. Although leukoreduction will add cost to a unit of blood, projections
indicate that leukoreduced blood will become the standard of care.
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of blood components transfused in the USA that were leuko-
reduced were 17.6% and 18.3% and for platelets 16.5% and
15.5%, respectively [3]. Surgical patients and those with
gastrointestinal bleeds are the groups most likely to receive
nonleukoreduced blood, in part because of the emergent
need for blood.
When a unit of blood (approximately 500 ml) is collected,
about 2 billion (2 × 109) white cells are present. Even with
blood component processing, 90% of these cells remain with
the RBCs, primarily as granulocytes; 8% of cells (2 million)
remain with platelets as mononuclear cells; and 2% of cells
(10 million) remain in an aliquot of fresh frozen plasma. The
intent of leukoreduction is to decrease the number of white
cells in the aliquot, but even the 0.0005% of cells left after
leukoreduction leaves 5000 residual leukocytes. Filtering of
the white cells can lead to a 5–10% loss in the number of
RBCs recovered per unit. These losses may be justified,
however, because they are balanced in part by the improved
quality of the filtered RBC unit.
Although it is the most common transfusion reaction, febrile-
associated transfusion reaction is due to clerical error and is
self-limited. Fatal hemolytic transfusion reaction still occurs in
1 per 500,000 units of blood transfused. The Canadian
Blood Service implemented prestorage universal leukoreduc-
tion to control febrile reactions [3]. Universal prestorage
leukoreduction has resulted in decreased fever episodes and
antibiotic use after RBC transfusion, with a reduction in mor-
tality [4]. Suggestions have also been made that transfusion-
related acute lung injury may be due to the presence of
allogeneic leukocytes in stored RBC products, although most
cases of transfusion-related acute lung injury are believed to
be due to the passive transfusion of anti-HLA antibodies that
react with recipient neutrophils.
Up to 30% of platelet transfusions lead to a febrile reaction;
however, this may be secondary to the release of platelet-
specific chemokines rather than the chemokines released by
contaminating leukocytes. In a multicenter study conducted in
patients with leukemia and sponsored by the US National
Institutes of Health, a difference in platelet refractoriness did
not lead to clinical differences. On the other hand, the Ameri-
can Society of Clinical Oncology found level I grade A evi-
dence, and recommended that only leukoreduced products
be used in patients with acute myeloid leukemia. This is
because alloimmunization against histocompatibility antigens
occurs in many recipients of multiple random donor platelet
transfusions, and is the most important long-term complica-
tion of platelet transfusion [5].
Leukoreduction may occur in two forms: prestorage filtration
or poststorage filtration. The most common form used in
Europe and the USA is prestorage leukoreduction, which
removes leukocytes before they can contribute to the storage
lesion (RBCs) or transfusion reactions (platelets/RBCs). The
process allows the opportunity for better quality control, has
not been associated with acute hypotensive episodes, and
eliminates the need for transfusion services to manage filter
inventories and for nursing staff to maintain multiple blood
administration protocols. Table 1 lists the advantages of uni-
versal leukocyte reduction. Prestorage leukoreduction not
only decreases the incidence of certain virus transmissions
but also eliminates the delay associated with filtering blood in
a patient who requires blood to be administered urgently.
Only one type of filter is needed, allowing standardization to
occur, obviating the need to train technicians and nurses on
the procedure, and eliminating the clotting of filters during a
transfusion.
One advantage that poststorage filtration may have is that the
filter used with transfusion administration may remove unde-
sired substances that accumulate during storage. No studies
to date have shown benefits from this type of filtration.
Table 2 summarizes the disadvantages of leukoreduction.
A study of elective orthopedic surgery patients confirmed the
presence of T-cell-mediated immunity after allogeneic transfu-
sion. With buffy coat depleted or white blood cell filtered
RBCs, alloantigen-induced T-cell proliferation was signifi-
cantly reduced [6]. However, in a group of patients with
advanced HIV infection, in which T-cell immunity is important,
leukoreduction provided no clinical benefit with respect to
HIV, CMV, or cytokine activation [7].
Table 1
Advantages of universal leukocyte reduction
Reduction in transfusion reactions; HLA alloimmunization; and CMV, HTLV-I, EBV, HHV-6 and HHV-8 transmission
Improved RBC quality
Reduction in parasite and prion transmission, bacterial sepsis, and acute lung injury
May decrease postoperative abdominal infection, morbidity and mortality in cardiac surgery, and multisystem organ failure
Avoids errors, decreases workload, and simplifies blood bank inventory
No need for a filter, saving time and education
Reproduced with permission from [1]. © 2001, American Society of Clinical Pathologists. CMV, cytomegalovirus; EBV, Epstein–Barr virus; 
HHV, human herpesvirus; HTLV, human T-cell leukemia virus; RBC, red blood cell.S29
Six studies [8–13] suggested that leukoreduction is benefi-
cial in preventing postoperative complications in patients
undergoing surgery, but two studies [14,15] showed no
benefit. Because of issues regarding study design, data
analysis, and other factors, these findings are still a subject of
debate. There are no data indicating that patients undergoing
abdominal surgery will benefit. On the other hand, two
studies [12,13] were published that reported evidence of
improvement in morbidity and mortality. One large study [13]
found a 50% decrease in the mortality rate and a decrease in
postoperative infection as a secondary end-point in patients
undergoing cardiac surgery receiving leukoreduced blood.
The largest prospective randomized study of leukoreduction
[16] enrolled 2780 patients, and documented no differences
in the outcome measures studied, including in-hospital mor-
tality, hospital length of stay, intensive care unit length of stay,
postoperative length of stay, antibiotic usage, and readmis-
sion rate. Subgroup analyses based on age, sex, amount of
blood transfused, and category of surgical procedure showed
no effect of leukocyte reduction. Patients who received leuko-
cyte-reduced blood exhibited a lower incidence of febrile
reactions (P = 0.06). In that important study no beneficial
effect from leukocyte reduction was demonstrated.
A recent meta-analysis [17] reviewed all randomized con-
trolled trials evaluating leukocyte-reduced transfusions and
mortality. There was no association between transfusion and
mortality across 14 trials reporting on short-term mortality
(summary odds ratio 1.20, 95% confidence interval
0.87–1.65) or across three trials reporting on long-term mor-
tality (summary odds ratio 0.87, 95% confidence interval
0.64–1.19). Subgroup analysis suggested an association
between non-leukocyte-reduced blood transfusion and
increased short-term mortality in cardiac surgery patients.
No prospective randomized studies have yet investigated
whether leukoreduction of blood is associated with improved
outcome in critically ill patients specifically.
Leukoreduction of blood can add approximately $100 to the
cost of a unit of blood. In the State of Rhode Island, with a
population of 1 million, the cost of leukoreduction is
US$1,466,250 [18]. Extrapolating this figure to universal
leukoreduction in the entire USA yields an annual cost of
around $319 million, but this does not take into account the
above-mentioned cost savings associated with reduced time,
resources, and effort (Table 2).
Emerging scientific and clinical evidence demonstrates that
leukoreduction technology is an effective means to reduce
the risk for three complications of transfusions [19]: HLA
alloimmunization, CMV transmission, and recurrent febrile
nonhemolytic transfusion reactions. Notwithstanding the
ongoing debate on the merits versus the disadvantages of
universal leukoreduction, most projections indicate that within
the next few years all blood in the USA will be leukoreduced.
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